psoriasis vulgaris
Conditions
Interventions
experimental group:Topical monotherapy+Panthiopheniramine (once daily, 1 capsule/time, taken with meals)
control group:Topical monotherapy
Sponsors
The First Medical Center of the People's Liberation Army General Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Age>18 years old, male or female not limited; 2. Clinical diagnosis of plaque psoriasis vulgaris ( PASI score<10points) 3. Have not received systemic treatment for psoriasis within two months 4. Not received any topical medication treatment within two weeks 5. The patient has concomitant elevated blood lipids (those who regularly take lipid-lowering drugs will continue to maintain their condition during the trial period, and will be treated with pantoprazole; patients who do not usually take medication will be treated with pantoprazole) 6. Voluntarily sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1. History of clinical diagnosis of special types of psoriasis (erythrodermic type, articular type, etc.); 2. Suffering from other autoimmune diseases (such as Sjogren's syndrome); 3. Individuals who require hospitalization or intravenous anti infective treatment due to active infection within the first 4 weeks; 4. Patients with hypertension and hyperglycemia that are difficult to control with medication (glycated hemoglobin A1c [HbA1c]>8% or >64mmol/mol); 5. Patients diagnosed with grade III or IV congestive heart failure according to the New York 6.Heart Association (NYHA) functional classification during the screening period; 6. Patients who experience myocardial infarction, acute coronary syndrome, stroke, or severe respiratory disease within 26 weeks prior to the start of the treatment period; 7. Pregnant or lactating patients, as well as men and women with fertility plans during the trial period; 8. Patients with a history of malignant tumors, except for tumors that have been cured or relieved for >= 5 years, skin basal cell or squamous cell carcinoma that has been surgically removed, or carcinoma in situ in any location; 9. Have used any investigational drug within the 28 days prior to screening, or within the 5 half lives of the investigational drug; 10. The researchers determined that there were other reasons why it was not suitable to participate in this clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Psoriasis area and severity index, PASI; | — |
Secondary
| Measure | Time frame |
|---|---|
| triglyceride;total cholesterol; | — |
Countries
China
Contacts
Public ContactLi Chengxin
The First Medical Center of the People's Liberation Army General Hospital
Outcome results
None listed